Valneva (VLA) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
8 Jul, 2026Executive summary
Q1 2025 revenues rose 50.3% year-over-year to €49.2 million, with product sales up 51.2% to €48.6 million, driven by recovery from supply shortages and strong demand.
Net loss was €9.2 million, reversing a prior year profit that included a €90.8 million one-time Priority Review Voucher sale.
Operating cash burn reduced by 71% to €8.1 million, with cash and cash equivalents at €153 million at quarter-end, excluding €14.2 million from an April ATM transaction.
Achieved significant regulatory milestones for IXCHIQ, including label extensions, new approvals in the UK, Europe, and Brazil, and a new IXIARO contract with the US Department of Defense.
Advanced clinical pipeline with positive IXCHIQ data in adolescents and pediatrics, and initiated phase II studies for Shigella and ZIKA vaccine candidates.
Financial highlights
Product sales reached €48.6 million, up 51.2% year-over-year; IXIARO/JESPECT sales rose 65.5% to €27.5 million, DUKORAL sales grew 9.4% to €12.3 million, and IXCHIQ sales increased to €3.0 million.
Gross margin on commercial products (excluding IXCHIQ) improved to 62.7% from 43.9% year-over-year; IXIARO gross margin reached 72.6%, DUKORAL 52.2%.
Adjusted EBITDA was €(0.6) million, compared to €73.0 million in Q1 2024, which included a one-time €90.8 million gain from a PRV sale.
Operating loss was €6 million; net loss for Q1 2025 was €9.2 million.
R&D expenses increased to €15.0 million from €13.1 million year-over-year.
Outlook and guidance
FY2025 product sales guidance reiterated at €170–180 million and total revenues at €180–190 million.
R&D expenses expected between €90–100 million, partially offset by grants and tax credits.
Targeting operational cash burn below €30 million, more than 50% lower than 2024, with a path to sustained profitability from 2027 based on successful Lyme vaccine commercialization.
Commercial business expected to be cash-flow positive, with focus on gross margin improvement and cost-efficient manufacturing.
Latest events from Valneva
- Revenue and product sales fell, but cash position improved and 2026 guidance reaffirmed.VLA
Q2 2026 - Late-stage Lyme vaccine, strong pipeline, and €135–€150m 2026 sales guide strategic growth.VLA
Company presentation - Registers 31.8M shares for resale; warrant exercises could yield up to €47M for growth.VLA
Registration filing - Lyme vaccine filing expected this autumn, with major catalysts ahead in 2024 and 2025.VLA
Jefferies Global Healthcare Conference 2026 - Leading specialty vaccine developer targets €135–€150m sales in 2026, driven by innovative pipeline.VLA
Investor presentation - Q1 2026 revenues and margins declined, but cost controls and pipeline progress support outlook.VLA
Q1 2026 - 2025 revenues rose to €174.7M, proprietary sales up 9%, and key Lyme vaccine data ahead.VLA
Q4 2025 - Lyme vaccine phase 3 data expected H1 2026, with major growth and R&D expansion planned.VLA
TD Cowen 46th Annual Health Care Conference - Net profit of €24.7M, strong vaccine sales, and pipeline progress support positive outlook.VLA
Q3 2024